FENNEC PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
FENC$10.58-2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(U.S. dollars in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended | ||||||
| · · December 31, · · December 31, | ||||||
| | 2024 | 2023 | ||||
| | | | | | | |
| Cash flows provided by (used in): · · | ||||||
| Operating activities: · · | ||||||
| Net loss | | $(436) | | $(16,045) | ||
| Adjustments to reconcile net loss to net cash provided by / (used in) operating activities: | | | | | ||
| Inventory reserve | | | 517 | | | — |
| Allowance for credit losses | | | 3,803 | | | — |
| Amortization of contract asset | | | 800 | | | — |
| Amortization of debt access fees | | 21 | | 221 | ||
| Amortization of debt discount | | | 138 | | | 66 |
| Unrealized loss on securities | | | 81 | | | 39 |
| Stock-based compensation | | 5,061 | | 5,354 | ||
| PIK interest | | | 52 | | | — |
| Changes in operating assets and liabilities: | | | | | ||
| Accounts receivable | | | (7,873) | | | (7,269) |
| Prepaid expenses | | (505) | | 104 | ||
| Inventory | | | 579 | | | (1,580) |
| Other assets | | 796 | | 3 | ||
| Accounts payable | | (537) | | 1,388 | ||
| Accrued liabilities | | (326) | | 576 | ||
| Contract liability | | | 24,809 | | | — |
| Net cash provided by / (used in) operating activities | | 26,980 | | (17,143) | ||
| | | | ||||
| Financing activities: | | | ||||
| Issuance of shares, options exercise | | 1,301 | | 1,716 | ||
| Payment of long-term debt | | | (13,000) | | | 4,997 |
| Debt discount | | | — | | | 3 |
| Cash paid for taxes on restricted share release | | | (176) | | | (78) |
| Deferred issuance costs | | (1,740) | | — | ||
| Net cash (used in) / provided by financing activities | | (13,615) | | 6,638 | ||
| | | | | | | |
| Increase/(decrease) in cash and cash equivalents | | | 13,365 | | | (10,505) |
| Cash and cash equivalents - Beginning of year | | | 13,269 | | | 23,774 |
| Cash and cash equivalents - End of year | | $26,634 | | $13,269 | ||
| | | | | | | |
| Supplemental disclosures of cash flow information: | | | | | | |
| Non-cash investing and financing activities: | | | ||||
| Right-of-use assets obtained in exchange for operating lease liabilities | | $2 | | $— | ||
| Financed insurance policy | | $386 | | $403 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.